MCRPC
Clinical trials for MCRPC explained in plain language.
Never miss a new study
Get alerted when new MCRPC trials appear
Sign up with your email to follow new studies for MCRPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new radioactive drug (177Lu-rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose to shrink tumors or lower PSA levels. About 82 men will take part acr…
Matched conditions: MCRPC
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated May 17, 2026 06:17 UTC
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see how the drug…
Matched conditions: MCRPC
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:16 UTC
-
New radioactive drug targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug called [225Ac]Ac-AKY-2519 in people with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The drug targets a protein (B7-H3) on cancer cells to deliver radiation directly to tum…
Matched conditions: MCRPC
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC